Ibrutinib Plus Rituximab Superior To Standard Treatment For Patients With Chronic Leukemia | Latest News RSS feed

Ibrutinib Plus Rituximab Superior To Standard Treatment For Patients With Chronic Leukemia - Latest News


Ibrutinib plus rituximab superior to standard treatment for some patients with chronic leukemia

An interim analysis of a large phase 3 clinical trial found that the combination of ibrutinib plus rituximab was superior to standard treatment for patients age 70 and younger with previously ... read more

Phase 3 trial finds ibrutinib in combo with rituximab superior to standard treatment for some patients with CLL

An interim analysis of a large phase 3 clinical trial found that the combination of ibrutinib plus rituximab was superior to standard treatment for patients age 70 and younger with previously ... read more

Clinical Challenges: Selecting First-Line Therapy in CLL

Recent phase III trials and FDA approvals in first-line chronic lymphocytic leukemia (CLL) have altered the landscape for patients requiring treatment ... ibrutinib (Imbruvica) with or without ... read more

Looking for another news?


Ibrutinib Regimens Have Superior PFS Compared With Chemoimmunotherapy in Older Patients With Untreated CLL

Chronic lymphocytic leukemia ... to standard chemoimmunotherapy. The researchers compared chemoimmunotherapy with bendamustine and rituximab with ibrutinib alone and ibrutinib plus rituximab to ... read more


Ibrutinib outperforms chemoimmunotherapy in older patients with chronic lymphocytic leukemia

Results from an multi-institutional, phase 3 clinical trial show that older patients with chronic lymphocytic leukemia ... ibrutinib to bendamustine plus rituximab, a more effective regimen. "Our ... read more

New drug combination for treating Chronic Leukemia

Combination of ibrutinib plus rituximab was found superior to the old treatment for patients aged ... suffering from chronic lymphocytic leukemia could benefit more by using new combination ... read more

Imbruvica May Be Superior to Standard of Care in Elderly Patients with CLL

Imbruvica (ibrutinib) may be superior to standard of care in elderly patients with untreated chronic lymphocytic leukemia (CLL), according to ... a type of chemotherapy, and Rituxan (rituximab), an ... read more

Ibrutinib and Rituximab for Untreated CLL: 'Practice Changing'

beat the current gold standard of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with untreated chronic lymphocytic leukemia (CLL) in a large trial funded by the National ... read more

Ibrutinib Superior to Chemoimmunotherapy in Treatment-Naive CLL

Treatment with ibrutinib for chronic lymphocytic leukemia (CLL) resulted in a favorable benefit/risk profile for patients ... with rituximab vs bendamustine and rituximab or fludarabine, ... read more

Ibrutinib plus rituximab superior to standard treatment for patients with chronic leukemia

San Diego - An interim analysis of a large phase 3 clinical trial found that the combination of ibrutinib plus rituximab was superior to standard treatment for patients age 70 and younger with ... read more

Ibrutinib Alone Wins in Older CLL Patients

SAN DIEGO -- First-line ibrutinib (Imbruvica) with or without rituximab topped standard chemoimmunotherapy in older chronic lymphocytic leukemia (CLL) patients ... to the modern standard treatment of ... read more

Ibrutinib Alone Better Than Chemoimmunotherapy as Frontline in Older Patients With CLL

According to the results of Alliance A041202, an international multicenter phase 3 trial, ibrutinib produces superior progression-free survival (PFS) compared with standard ... plus rituximab in ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us